Recombinant SARS-CoV-2 Neutralizing Antibody Blocks Spike RBD-ACE2 Interaction; SPR Characterization

Cayman Chemical, in collaboration with Thermo Fisher Scientific, investigated the ability of a SARS-CoV-2 neutralizing antibody (nAb) to block the spike S1 RBD-ACE2 interaction using CryoEM and SPR. This poster presentation focuses on the production and characterization of recombinant proteins hACE2 and S1 RBD wild-type and Alpha and Beta variants, an evaluation of the binding kinetics and affinity measurements for the nAb towards S1 RBD in the presence of ACE2, and how the knowledge presented in this study will help design more potent vaccines against new SARS-CoV-2 variants.